Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beam me later: Prepectoral vs subpectoral breast reconstruction before postmastectomy radiotherapy - A systematic review and meta-analysis.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2025

Same author

The impact of breast reconstruction compared with no reconstruction on breast cancer-related lymphedema: A systematic review and meta-analysis.

Surgery·2025

Same author

[Individualized oncoplastic breast surgery].

Ugeskrift for laeger·2025

Same author

Go Pre or Stay Sub? Immediate implant-based breast reconstruction: A systematic review and meta-analysis.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2025

Same author

Hot topics in breast reconstruction world wide.

Gland surgery·2025

Same author

Mesenchymal Stem Cell Therapy Fails to Improve Fat Graft Retention: Cryopreserved and Cultured Syngeneic and Allogeneic Mesenchymal Stem Cells in a Rat Model.

Plastic and reconstructive surgery·2025

Search research articles

Related Experiment Video

Updated: May 9, 2026

A Patient-Derived Xenograft Model for Venous Malformation

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Haemangioma and propranolol.

Tine Engberg Damsgaard¹, Jesper Vandborg Bjerre

¹Departments of 1Plastic Surgery.

Journal of Plastic Surgery and Hand Surgery

|July 11, 2013

Summary

A slow-involuting segmental hemangioma recurred after conventional treatment. Propranolol effectively treated the hemangioma in a young girl, leading to regression confirmed by MRI.

Area of Science:

Vascular Anomalies
Pediatric Dermatology
Pharmacology

Background:

Slow-involuting segmental hemangiomas (SIH) are congenital vascular malformations.
Conventional treatments for SIH can have limitations and recurrence is possible upon cessation of therapy.

Observation:

A 2.5-year-old female presented with a recurrent SIH after initial conventional treatment.
Treatment cessation led to hemangioma proliferation, indicating a need for effective long-term management.

Findings:

Propranolol, a beta-blocker, was administered to the patient following published evidence of its efficacy in treating hemangiomas.
Magnetic resonance imaging (MRI) and clinical follow-up confirmed the complete regression of the SIH after propranolol treatment.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Related Experiment Videos

Last Updated: May 9, 2026

A Patient-Derived Xenograft Model for Venous Malformation

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Implications:

Propranolol represents a promising therapeutic option for managing slow-involuting segmental hemangiomas, particularly in cases of recurrence.
This case highlights the potential of targeted pharmacological intervention in achieving sustained regression of challenging vascular lesions.